CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

OBJECTIVE: To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit–risk assessment of nataliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lieberman, Linda A., Zeng, Wanyong, Singh, Carol, Wang, Wenting, Otipoby, Kevin L., Loh, Christine, Plavina, Tatiana, Gorelik, Leonid, Ransohoff, Richard M., Cahir-McFarland, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776091/
https://www.ncbi.nlm.nih.gov/pubmed/26718566
http://dx.doi.org/10.1212/WNL.0000000000002314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776091/
https://www.ncbi.nlm.nih.gov/pubmed/26718566
http://dx.doi.org/10.1212/WNL.0000000000002314

Ejemplares similares